Tsuchiya Hiroyuki, Shiota Goshi
Division of Medical Genetics and Regenerative Medicine, Department of Genomic Medicine and Regenerative Therapy, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan.
Yonago Acta Med. 2021 Jan 6;64(1):1-11. doi: 10.33160/yam.2021.02.002. eCollection 2021 Feb.
Hepatocellular carcinoma (HCC) is a malignant tumor with poor prognosis, and is one of the leading causes of cancer-related deaths worldwide. Recently, the development of therapeutic drugs via novel mechanisms of action, involving molecular-targeted drugs and immune checkpoint inhibitors, has progressed in the field of HCC. However, the recurrence rate remains high, and further improvement of the prognosis of patients with HCC is urgently needed. Cancer stem cells (CSCs) are a promising target for further development of novel anti-cancer drugs because they are reportedly involved in tumor initiation, maintenance, recurrence, and resistance to conventional therapies. Although several studies have already been conducted, the functions and roles of CSCs in the development and progression of tumors remain to be elucidated. In this review article, we will clarify the fundamental knowledge of CSCs necessary for the understanding of CSCs and will outline so-far identified markers specific to liver CSCs and the pathological and therapeutic implications of CSCs in HCC.
肝细胞癌(HCC)是一种预后不良的恶性肿瘤,是全球癌症相关死亡的主要原因之一。最近,通过新作用机制开发治疗药物(包括分子靶向药物和免疫检查点抑制剂)在HCC领域取得了进展。然而,复发率仍然很高,迫切需要进一步改善HCC患者的预后。癌症干细胞(CSCs)是新型抗癌药物进一步开发的一个有前景的靶点,因为据报道它们参与肿瘤的起始、维持、复发以及对传统疗法的耐药性。尽管已经进行了多项研究,但CSCs在肿瘤发生和发展中的功能和作用仍有待阐明。在这篇综述文章中,我们将阐明理解CSCs所需的基础知识,并概述迄今为止已确定的肝脏CSCs特异性标志物以及CSCs在HCC中的病理和治疗意义。